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Targeted Temperature Management in Subarachnoid Haemorrhage 
Emanuela Keller, Neurocritical Care Unit, University Hospital Zurich, Switzerland 
Patients with subarachnoid haemorrhage (SAH) can benefit from hypothermia but the 
mechanisms by which this occurs are poorly understood. The pathophysiology following SAH 
is complex. Cerebral blood flow (CBF) through the capillaries is affected by several factors 
including cerebral vasospasm (CVS) but also by CPP and resistance at the arteriolar and 
possibly venous levels. Alterations in the latter two factors may manifest as slowed circulation 
time and poor vessel filling as seen on angiography but these cannot be necessarily be 
correlated with CVS.31 Following SAH, there is a strong inflammatory response that is induced 
by the breakdown of erythrocytes in the subarachnoid space. This reaction induces secondary 
ischaemia due to vasospasm but also contributes to the development of brain oedema. To 
prevent such oedema, early intervention in the inflammatory cascade is essential.32  
The damaging effect of inflammatory cytokines was demonstrated in a study of 138 patients 
with SAH.33 Unfavourable outcome (Glasgow Outcome Scale [GOS] 1–3) and delayed 
ischaemic neurological deficits (DINDs) were significantly associated with elevated blood IL6 
levels during the early phase (p=0.023 and p=0.026, respectively). It was suggested that IL6 
levels could be a useful parameter to monitor following SAH. A pilot study (n=15) reported that 
IL6, tumour necrosis factor α (TNF α) and IL1β increase in blood and cerebrospinal fluid in 
patients after SAH although IL6 was at 100-fold higher levels in CSF than blood.34  
Hypothermia, with a target range of 33–34°C using combined therapy with endovascular 
cooling and barbiturate coma, markedly reduced both IL6 and IL1β (p<0.001 for both) 
indicating its efficacy in attenuating the inflammatory cascade.  
The ratio between IL6 levels in the CSF and plasma, as a parameter for intrathecal synthesis, 
furthermore, was significantly lower in patients who received combined therapy compared with 
those who did not receive it (p=0.014). 
Other work on adult rats indicates that hypothermia reduces vasospasm and decreases the 
reduction in cerebral blood flow and oxygenation following SAH but the greatest benefit is 
gained when the treatment is within hours after aneurysm rupture.35 
Cooling the brain in SAH is likely to reduce metabolism, however, the optimal target 
temperature has not been determined. Some studies have shown that, while patients are 
cooled, uncoupling between CBF and CMRO2 occurs to the extent that CBF exceeds the 
metabolic demand. This phenomenon is known as luxury perfusion.36 This concept was 
supported by a small case series of patients with SAH and hypothermia (33–34°C) provided 
some preliminary evidence of hypothermia-induced luxury perfusion in which a larger decrease 
in CMRO2 (54.3%) compared with CBF (35.7%) was observed.37 
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Fever is the most frequent symptom in SAH, occurring in approximately 75% of patients and 
is strongly associated with death or severe disability as outcomes.38 In SAH, fever is more 
common than hyperglycaemia, hypertension, pneumonia and delirium. A meta-analysis of 24 
studies in 2010 found that fever during acute hospitalisation for SAH was consistently linked 
with worsened outcome and increased mortality.39 Antipyretic medications, surface cooling and 
intravascular cooling may reduce fevers but the benefits from these measures may be offset 
by negative consequences of shivering.39 The potential negative consequences of fever 
reduction were also indicated by a study of 21 consecutive aneurysmal SAH patients who were 
given diclofenac.40 This treatment effectively reduced body temperature but this led to 10% 
decrease in mean arterial pressure and CPP (p<0.001) and a 13% decrease in PbtO2 and 
brain hypoxia in 38% of patients. This suggested that fever reduction in SAH using diclofenac 
is not always beneficial and should be exercised with care. 
Intravascular cooling can also be associated with thromboembolic events. In a study of 122 
patients, among those with central venous lines (n=79) 5% had deep vein thromboses (DVT) 
or pulmonary embolism (PE).41 Among those with endovascular cooling catheters, however, 
(n=43) 37% had DVT or PE (52% in those treated for fever and 23% for those treated with 
hypothermia). In the treatment of fever in SAH, therefore, there is a need for prospective 
controlled trials that investigate the side effects; they should possibly use surrogate markers 
to determine outcomes including such as cerebral haemodynamics and metabolism, 
inflammatory response and secondary brain injuries. 
Hypothermia treatment is not always associated with favourable outcomes. This was shown in 
a study of 441 consecutive patients with SAH in which 100 patients developed raised ICP or 
symptomatic CVS that was refractory to treatment.42 Patients were treated with TTM using ice, 
water blankets or intravascular cooling (33–34oC) which was maintained until intracranial 
pressure normalized, CVS resolved, or there were severe side effects. Among these patients, 
only 25% with raised ICP, 57.1% with CVS and 26.5% with ICP/ISV showed favourable 
outcomes (Glasgow Outcome Scale 4 or 5). It was concluded that prolonged systemic 
hypothermia should be considered a last resort option in SAH with raised ICP or CVS that is 
resistant to treatment. A more recent pilot study, however, showed more positive findings for 
therapeutic hypothermia (TTM) in SAH.43 A group of 12 patients with SAH who received early 
TTM (within 48 h) showed reduced delayed cerebral ischaemia (DCI) and microvascular 
spasm compared with 24 matched patients from an SAH database. TTM significantly 
decreased macrovascular spasm and peak spastic (p < 0.05). The frequency of DCI was 
reduced from 87.5% in non-TTM to 50% in TTM-treated patients, creating a preventive risk 
ratio of 0.33 (p=0.036). Favourable functional outcomes were significantly more frequent in 
TTM-treated patients (66.7% vs. 33.3% of non-TH-treated patients, p=0.06 – see Figure 4). 
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 Animal studies have improved the understanding of SAH pathophysiology 
 Intravascular catheters are associated with increased risk of thrombosis 
 Larger retrospective case series show that TTM is a last resort treatment of 
intracranial hypertension and vasospasm 
 Findings in a recent prospective pilot study showed that TTM treatment can be 
beneficial in high-grade SAH patients 
 A prospective randomized study in high-grade patients with prophylactic TTM is 
needed and should include a few centres with a very strictly controlled treatment 
protocol 
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Figure 4 
Effect of hypothermia treatment versus no hypothermia treatment on outcomes in a series of patients with subarachnoid haemorrhage 
 
 
 
Source: Karamatsu et al., 201543 
